Cytarabine Alternating with Decitabine

Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
160 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Chemotherapy, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1540
NCT Identifier
NCT01515527

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.